

# KÃ<sup>a</sup>nia V Dos Santos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/895491/publications.pdf>

Version: 2024-02-01

9  
papers

115  
citations

1683934  
5  
h-index

1474057  
9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

209  
citing authors

#	ARTICLE	IF	CITATIONS
1	Proteomic analysis of <i>Escherichia coli</i> with experimentally induced resistance to piperacillin/tazobactam. <i>Research in Microbiology</i> , 2010, 161, 268-275.	1.0	40
2	Sub-Inhibitory Concentration of Piperacillin+Tazobactam May be Related to Virulence Properties of Filamentous <i>Escherichia coli</i> . <i>Current Microbiology</i> , 2016, 72, 19-28.	1.0	22
3	Isolation and identification of <i>Candida</i> species in patients with orogastric cancer: susceptibility to antifungal drugs, attributes of virulence in vitro and immune response phenotype. <i>BMC Infectious Diseases</i> , 2016, 16, 86.	1.3	16
4	In vitro activity of piperacillin/tazobactam and ertapenem against <i>Bacteroides fragilis</i> and <i>Escherichia coli</i> in pure and mixed cultures. <i>Journal of Medical Microbiology</i> , 2007, 56, 798-802.	0.7	12
5	Comparative activity of ertapenem and piperacillin+ tazobactam in a murine systemic infection model with <i>Bacteroides fragilis</i> and <i>Escherichia coli</i> . <i>Journal of Medical Microbiology</i> , 2007, 56, 1576-1579.	0.7	6
6	Drug-induced tolerance: the effects of antibiotic pre-exposure in <i>Stenotrophomonas maltophilia</i> . <i>Future Microbiology</i> , 2020, 15, 497-508.	1.0	6
7	Proteomic changes in <i>Bacteroides fragilis</i> exposed to subinhibitory concentration of piperacillin/tazobactam. <i>Anaerobe</i> , 2013, 22, 69-76.	1.0	5
8	Effect of antimicrobials on <i>Stenotrophomonas maltophilia</i> biofilm. <i>Future Microbiology</i> , 2021, 16, 83-93.	1.0	5
9	Low Serum Trough Concentrations and High Vancomycin Minimum Inhibitory Concentration in Methicillin-Sensitive <i>Staphylococcus aureus</i> From Hemodialysis Patients in Brazil. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 38-43.	1.0	3